latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/abbvie-waives-patent-rights-to-potential-coronavirus-drug-kaletra-8211-ft-57731998 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

AbbVie waives patent rights to potential coronavirus drug Kaletra – FT

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AbbVie waives patent rights to potential coronavirus drug Kaletra – FT

AbbVie Inc. is waiving global patent rights to its HIV therapy Kaletra — an antiviral drug being studied as a potential coronavirus treatment, the Financial Times reported.

With AbbVie's decision, generic versions of the drug will be available worldwide, the paper said, citing the Medicines Patent Pool, a non-governmental organization backed by the United Nations. The North Chicago-based pharma giant is the first drugmaker to waive its rights to profit from a drug that could potentially be used in the pandemic, according to the FT.

Kaletra, also known as Aluvia, is a combination of lopinavir and ritonavir approved to treat HIV-1 infection. The drug has patent protection until 2026 in certain areas, the FT said, citing medical database MedsPaL.

READ MORE: Sign up for our weekly coronavirus newsletter here, and read our latest coverage on the crisis here.

AbbVie said March 9 that it will support clinical studies and basic research to determine the antiviral activity, effectiveness and safety of Kaletra against COVID-19, the respiratory disease caused by the new coronavirus, known as severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. The company's announcement follows unconfirmed media reports in China claiming that its HIV regimen is effective against COVID-19.

However, a study published in the New England Journal of Medicine on March 18 found that Kaletra was not effective in treating COVID-19 among 199 Chinese patients, though the authors suggested outcomes might be improved if combined with other antivirals.

As of March 24, the COVID-19 pandemic has seen a total of more than 381,000 confirmed cases globally, with over 16,500 deaths, according to data from Johns Hopkins University's Center for Systems Science and Engineering.

SNL Image